FDA approves Sagent Pharma polymyxin B for injection, USP
polymyxin B is also intended to be used topically and subconjunctivally to treat eye infection associated by susceptible strains of Pseudomonas aeruginosa. The product includes PreventIV Measures packaging
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.